UBXN6 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
Images
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
Alternative names
UBX domain containing 1, UBX domain containing 2, UBX domain protein 6, UBX domain-containing protein 1, UBX domain-containing protein 6, UBXD1, UBXDC2, UBXN6_HUMAN
What's included?
Recommended products
UBXN6 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Knockout validation
- Sanger Sequencing, Western blot
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
- Concentration
Properties
- Gene name
- UBXN6
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing, Western blot
- Zygosity
- Homozygous
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
UBXN6 also known as UBXD1 is a protein with a molecular mass of approximately 48 kDa. This protein is expressed across various tissues showing higher levels in skeletal muscle heart and kidney. UBXN6 contains a UBX domain which is essential for its interactions with other proteins especially those in the ubiquitin-proteasome system. Mechanically UBXN6 acts as a cofactor modulating the functions of several cellular machineries involved in protein degradation.
- Biological function summary
Four words describe UBXN6's relevance in cellular homeostasis. UBXN6 plays an important role in the regulation of protein turnover as it is involved in the ubiquitin-proteasome complex. It assists in the disassembly of protein substrates tagged for degradation contributing to the maintenance of protein quality control within the cell. Through interaction with p97/VCP UBXN6 helps in processes like endoplasmic reticulum-associated degradation (ERAD) important for cellular response to misfolded proteins.
- Pathways
UBXN6's involvement extends to the autophagy and ubiquitin-proteasome pathways. In the ubiquitin-proteasome pathway it acts as a regulatory component favoring the removal of damaged or unnecessary proteins by acting with partners like p97/VCP. Through the autophagy pathway UBXN6 aids in cellular cleanup and recycling processes supporting cellular survival mechanisms during stress conditions. These pathways highlight UBXN6's integral role in protein quality control and cellular defense.
- Associated diseases and disorders
Four words explain UBXN6's clinical importance. Research links UBXN6 to neurological disorders such as amyotrophic lateral sclerosis (ALS) where misfolded proteins contribute to disease progress. Moreover UBXN6 relates to cancer especially in tumor progression where impaired protein degradation can lead to uncontrolled cell growth. In both cases UBXN6 interacts closely with p97/VCP offering potential therapeutic targets for drug development aimed at modulating its activity to restore cellular balance.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Western blot - Human UBXN6 (UBXD1) knockout HEK-293T cell lysate (ab258747)
Lane 1:Wild-type HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate (20 ug)
Lane 2:UBXN6 knockout HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate (20 ug)
Lane 3:HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate (20 ug)ab81555 was shown to specifically react with UBXN6/UBXD1 in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line Human UBXN6 (UBXD1) knockout HEK-293T cell line ab266689 (knockout cell lysate ab258747) was used. Wild-type and UBXN6/UBXD1 knockout samples were subjected to SDS-PAGE. ab81555 and Anti-GAPDH antibody[EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) were incubated at room temperature for 2.5 hours at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Anti-UBXN6/UBXD1 antibody [2F8-24] (ab81555) at 1/500 dilution
Lane 1: Wild-type HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 20 µg
Lane 2: UBXN6 knockout HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 20 µg
Lane 2: Western blot - Human UBXN6 (UBXD1) knockout HEK-293T cell line (Human UBXN6 (UBXD1) knockout HEK-293T cell line ab266689)
Lane 3: HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 20 µg
SecondaryAll lanes: Western blot - Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) at 1/10000 dilution
Sanger Sequencing - Human UBXN6 (UBXD1) knockout HEK-293T cell lysate (ab258747)
Homozygous: 1 bp insertion in exon 2
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com